Eli Lilly is developing a groundbreaking drug, lepodisiran, to combat high LPA cholesterol levels prevalent in South Asians, ...

GLP-1 receptor agonists, originally introduced in 2006, have undergone significant advancements over the years. David Ricks, ...

Eli Lilly is advancing its diabetes and obesity treatment with an oral drug, orforglipron. In an exclusive interaction, CEO ...

Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, ...

Eli Lilly (NYSE: LLY) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable ...

Eli Lilly's CEO, David Ricks, reveals potential plans to manufacture the weight-loss drug Mounjaro in India as part of their global expansion.

LillyDirect will help provide services to millions of patients who have yet to be formally diagnosed with the disease.

Dr. Jitendra Singh, a renowned endocrinologist himself, emphasized the unique metabolic challenges faced by India due to its ...

Revenue for the blockbuster Eli Lilly drugs Mounjaro and Zepbound continues to grow, but not as much as expected. At the J.P. Morgan Healthcare Conference, Lilly CEO David Ricks explained why the ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

This is the latest sign of global healthcare giants doubling down on the market in recent years. Experts noted on Monday that ...

Eli Lilly plans to turn India into a growth market by addressing its diabetes and obesity challenges with its new treatment, ...